Background: Cutaneous lymphoma diagnosed after antietumor necrosis factor-a therapy (antieTNF-a) has been reported in the literature, yet a clear link between both events remains elusive.
Additionally, there is an increased risk for lymphoma with chronic use of immunosuppressive therapy such as cyclosporine, mercaptopurine, or antietumor necrosis factor-a (antieTNF-a) agents, yet the effects of these agents on CL remains controversial. 1, 2 Approximately 30 cases of CL arising after antieTNF-a therapy have been reported in the literature. 1, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] In some of those cases, MF resembling psoriasis or eczema was eventually diagnosed, with an unmasking of the lymphoma after the patient received the antieTNF-a agent. Herein, we describe our multiinstitutional set of patients in whom CLs were diagnosed after they had been exposed to antieTNF-a therapy.
MATERIALS AND METHODS
This is a case series derived from a multicenter retrospective chart review. Upon institutional review board approval, patients in whom CL had been diagnosed after therapy with antieTNF-a agents were included. A literature search of case series and case reports with the same inclusion criteria was also performed. Clinical data were collected from the electronic medical records system, including data on the following: sex; race; age of diagnosis of CL; disease for which the antieTNF-a agent was prescribed; other immunosuppressive treatment received; type of antieTNF-a agent received; time between when antieTNF-a therapy was started and CL diagnosis; type of CL diagnosed; blood parameters at diagnosis, such as lactate dehydrogenase level; flow cytometry of peripheral blood; S ezary cell count; T-cell receptor gene (TCR) rearrangement in the blood and skin; initial TNM staging for non-MF/ S ezary syndrome (SS) cases or TNMB staging for MF or SS cases; treatment received for CL; and outcome. Follow-up data were assessed from diagnosis to the most recent point in time for which adequate patient data existed. Skin biopsies performed before and after receipt of antieTNF-a therapy were reviewed along with immunohistochemistry data, when available. Descriptive statistics, including median (with range), were performed. The same data were also collected from published case series and case reports.
RESULTS
A total of 22 patients, 15 male and 7 female, were included in the study. CTCL was diagnosed in 20 patients and cutaneous B-cell lymphoma (CBCL) was diagnosed in 2.
CTCL
Clinical, histologic, and therapeutic details of the 20 patients with CTCL are reported in Table I . 21 The male-to-female ratio was 2:1, and the median age was 63 years (range, 21-76). Fifteen patients were white, 3 were black, and 2 were Hispanic. A primary skin disorder was the indication for the use of antieTNF-a agents in 75% of patients. The disease of most of these patients had been clinically diagnosed as psoriasis, psoriasiform dermatitis, or idiopathic erythroderma. With regard to the remaining 5 patients (25%), rheumatoid arthritis (RA) was diagnosed in 2, Crohn's disease in another 2, and sarcoidosis in 1 before use of antieTNF-a therapy. Of note, 3 of the 5 patients had a concomitant but unspecified dermatitis before initiation of the antieTNF-a agent.
Of the 18 patients with a skin disorder before initiation of an antieTNF-a agent, 15 had a skin biopsy performed. The most common histologic finding (46%) was psoriasis or psoriasiform dermatitis, with some cases revealing striking similarity to psoriasis vulgaris, including acanthosis, parakeratosis, and exocytosis of neutrophils. The biopsy results of the remaining 7 patients were reported as chronic spongiotic dermatitis, chronic lymphocytic dermatitis, or granulomatous dermatitis. We had the opportunity to retrospectively review 6 of these biopsy specimens, which in some cases showed rare atypical lymphocytes but for the most part failed to fulfill the histologic or immunohistologic criteria for CL. Only 2 patients with extensive skin disease had peripheral blood assessment performed before initiation of antieTNF-a therapy. Both had an abnormal population of fewer than 200 cells, 1 by morphology and the other by flow cytometry results deemed clinically nonsignificant.
The median time from disease onset to initiation of antieTNF-a therapy was 6 years (range, Before initiation of antieTNF-a therapy, skin biopsy and peripheral blood analysis should be considered in patients with atypical presentation of psoriasis to exclude CL.
had been treated with 6-mercaptopurine and/or azathioprine, and another 1 received cyclosporine A. Phototherapy had been given to 38% of patients (5 of 13) during their treatment course.
After initiation of antieTNF-a therapy, the majority of patients experienced worsening of their skin disease, and three patients developed new skin eruptions. One of them was a 21-year-old patient with symmetrically distributed erythematous and scaly plaques, biopsy-proven psoriasis, and a family history of psoriasis who developed de novo erythematous patches with a different distribution compared with his psoriasis (case 9).
The median time from the start of administration of an antieTNF-a agent to CTCL diagnosis was 6 months (range, 1-24). MF was diagnosed in patients, including 4 patients with the folliculotropic variant, 2 patients with SS, 3 patients with CTCL not otherwise specified (NOS), 1 patient with primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma, and 1 patient with primary cutaneous gd T-cell lymphoma. Stages are detailed in Table I . Limited blood involvement (B1 stage) was observed in 5 patients (45%) on blood smear, with 2 of these cases confirmed by flow cytometry. One patient with CTCL NOS had an abnormal population of more than 3000 cells, with a CD4 -/CD8
-null phenotype that did not coincide with the phenotype of the atypical lymphocytes of the skin biopsy specimen (case 1). This patient died from the CTCL 2 months after administration of the antieTNF-a agent. 22 At diagnosis of CTCL, serum lactate dehydrogenase level was abnormal in 7 patients (70%), all of whom had advanced disease; 81% of the patients had a T-cell clone present in their skin biopsy specimen, and 58% had a T-cell clone present in their peripheral blood. The same clonality in skin and blood was detected in 1 patient with MF, as well as in the 2 patients with SS. Histologic features and phenotype of the diagnostic skin biopsy specimens are shown in Table II . At the time of CTCL diagnosis, 3 biopsy specimens consistent with MF showed features of large cell transformation (LCT), and large cell morphology was observed in 1 patient with CTCL NOS (case 2).
The median time of follow-up for patients with available data (16 patients) was 25 months (range, 4-137). After discontinuation of the antieTNF-a agent, all patients received treatment according to their CTCL stage, except for 1 patient in whom subcutaneous nodules resolved spontaneously 7 months after the antieTNF-a agent was withdrawn (case 3). Six patients achieved complete remission, 5 patients achieved partial response, and 4 patients had no significant improvement with CTCL therapy. Three patients died from progressive disease ( Table I ).
CBCL
One patient was a 29-year-old white man who presented with enlarged erythematous plaques on both lower legs after 8 months of etanercept therapy for RA. His skin biopsy specimen showed features consistent with primary cutaneous marginal zone lymphoma with Ig k light chain restriction and absence of Epstein-Barr virus encoded RNA1. The results of bone marrow biopsy were negative for lymphoma. After treatment with radiation, CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisone), and bortezomib, the patient achieved complete remission during a follow-up time of 3 years.
The second patient was a 53-year-old white man in whom primary cutaneous follicular B-cell lymphoma (PCFL) had been diagnosed 1 month after he had begun taking adalimumab for psoriasis and psoriatic arthritis. This patient received methotrexate, phototherapy, and acitretin before biologic therapy. Etanercept was prescribed initially, and after several years, he was switched to adalimumab to treat recalcitrant cutaneous psoriasis. Four weeks after this switch, he developed an erythematous plaque on the scalp that was histologically consistent with PCFL with large cell morphology. Cells were positive for Bcl-6 and negative for MUM1, Bcl-2, and Epstein-Barr virus encoded RNA1. Bone marrow biopsy showed no evidence of involvement by lymphoma. After radiation, the patient achieved complete remission and resumed treatment with etanercept for psoriasis/psoriatic arthritis without recurrence of the PCFL at 9 years of follow-up.
Literature review
We identified 31 additional published cases in which CL was diagnosed after exposure to an antieTNF-a agent (Table III) S ezary syndrome TNF-a: tumor necrosis factor-a these previously reported patients, 20 received an antieTNF-a agent for treatment of a systemic disease such as RA, inflammatory bowel disease, spondyloarthropathy, or psoriatic arthritis. Six of the 20 patients had a concurrent poorly characterized skin eruption. Eleven patients received an antieTNF-a agent for treatment of psoriasis, psoriasiform dermatitis, or nonspecific dermatitis. Of the 17 patients with any type of dermatosis, more than half either did not have a biopsy or had a biopsy with inconclusive results before initiation of an antieTNF-a agent. The median time of treatment with an antieTNF-a agent until CL diagnosis was 5.5 months (range, 0.5-96 months). MF or SS was diagnosed in 19 patients, 3 of whom had the folliculotropic variant and 4 of whom had LCT. Cytotoxic lymphomas were diagnosed in 5 patients, including subcutaneous panniculitis-like T-cell lymphoma, primary cutaneous gd T-cell lymphoma, dermal CD8
1 T-cell lymphoma, and primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma. Two patients developed a CD30 1 lymphoproliferative disorder. Other CLs were found in the remaining 5 patients (cutaneous Hodgkin's lymphoma in 2 patients, small/medium pleomorphic T-cell lymphoma in 2, and chronic adult T-cell leukemia/lymphoma in 1). Of the 19 patients with MF or SS, 17 had stage data available; 13 presented with early-stage disease (IA or IB), 2 with stage IIB, and 4 with stage IVA. The median time of follow-up was 11 months (range, 0.7-19 months), and the majority of these patients achieved complete remission or partial response. Only 1 developed progressive disease from patch to tumor stage. Six patients died, mostly for reasons unrelated to CL or because of CL treatment complications.
DISCUSSION
We describe a cohort of patients with CL diagnosed after exposure to antieTNF-a agents. Compared with in the cohort identified from the literature, a higher frequency of advanced disease was observed in our patient population. This difference might be explained by the inclusion criteria of the selected cohort. Whereas our inclusion criteria considered all cases in which CL was diagnosed after antieTNF-a therapy, some case series specifically excluded patients whose disease was misdiagnosed as psoriasis or eczema before use of biologic therapy. It is known that addition of immunosuppressive therapy in patients with CL often leads to disease progression. 20, 28 Our data underscore the risk for progression of previously undiagnosed CL when antieTNF-a therapy is used with the intent to treat a nonmalignant skin condition, likely because of the immunosuppressive properties of the treatment. Similar findings were observed in a recent publication that included CTCL cases exposed to any type of immunosuppression treatment, including cyclosporine, azathioprine, mycophenolate mofetil, and antieTNF-a agents. 20 Skin biopsies in the reported cases showed a high prevalence of LCT in the biopsy specimens of those patients with MF or SS and large cell morphology in the biopsy specimens of those with other types of CL, which is consistent with our findings. This corroborates prior reports of aggressive histologic features that indicate CL progression among patients given immunosuppressive therapy. 20, [28] [29] [30] [31] The rarity of CTCL relative to more common conditions such as psoriasis and eczema, combined with the fact that CTCL (most commonly MF) can clinically and histologically mimic these conditions, increases the risk for misdiagnosis. In addition, a clinical diagnosis of psoriasis is often not confirmed with skin biopsy. It has been suggested that chronic lymphocyte-driven inflammatory states of psoriasis and atopic dermatitis plus the use of immunosuppressive therapies may help in selecting a malignant T-cell clone, provoking the development of CTCL. 28, 32 Controversy surrounds the true prevalence of CL in patients with atopic dermatitis and psoriasis. One group reported a significantly increased risk for development of CTCL in patients with moderate-to-severe psoriasis independent of the systemic therapy received (adjusted hazard ratio, 9.25; 95% confidence interval, 95%). Another group cites misdiagnosis of CTCL as eczema as a major confounding factor in reporting the true prevalence of CTCL in patients with atopic dermatitis. [33] [34] [35] We acknowledge the occasional difficulty in differentiating clinically and histologically between MF and psoriasis or eczema and have seen a similar situation, with fatal disease progression in case 1 of this series. Indeed, MF and SS are known to occasionally require multiple skin biopsies for diagnosis. Thus, close clinical monitoring and repeat biopsies with the use of immunohistochemistry and TCR gene rearrangement should be considered in ambiguous or atypical cases. In patients with extensive skin disease or erythroderma, flow cytometry and TCR gene rearrangement studies of peripheral blood can aid in diagnosis. 36 There are no previous case reports in the literature of CBCL diagnosed during or after antieTNF-a therapy. It is difficult to definitively establish a causal relationship between the development of CL and the use of antieTNF-a agents in our patients. However, the temporal association noted in the first case presented, in which erythematous plaques that had been stable for 11 years enlarged with antieTNF-a therapy, suggests that adalimumab-induced immunosuppression can accelerate a previously quiescent low-grade primary CL. The patient in the second case was treated with etanercept for several years, with PCFL appearing after 1 month of adalimumab therapy. After the patient achieved complete remission, etanercept therapy was restarted without CL recurrence. Reinitiating antieTNF-a therapy after remission of CTCL is controversial; it is supported by only 1 case report of a patient with short-term follow-up. 22 Whether treatment with antieTNF-a agents can be safely resumed in patients with remission of a lowgrade CL requires further investigation. A balance between the benefits and risks of using antieTNF-a therapy after a diagnosis of CL in patients with systemic diseases such as Crohn's disease or RA must be carefully assessed. Our series highlights a variety of presentations of CL associated with antieTNF-a agents. Most cases had a preceding dermatitis that was possibly mistaken for psoriasis or eczema on account of lack of definitive features of CTCL or early evolution of disease. The use of antieTNF-a therapy downregulates innate and adaptive immunity that might normally control proliferation of malignant lymphocytes, thereby unmasking the lymphoma. This may explain why most of the patients in our series had a more advanced stage, often with large cell morphology or transformation at the time of diagnosis.
These findings underscore the need for all physicians prescribing antieTNF-a therapy to include a review of any cutaneous symptoms and a thorough skin examination before initiation of biologic therapy. A word of caution to avoid the use of antieTNF-a agents in erythrodermic patients when there is any doubt of the psoriatic nature of the erythroderma has already been given. Moreover, the diagnosis must be reconsidered if erythroderma worsens after an antieTNF-a agent has been administered. 37 In selected cases, skin biopsy and specific peripheral blood studies, such as flow cytometry and T-cell rearrangement, should be considered to exclude CL before initiation of immunosuppressive therapies. In addition, close monitoring and repeat biopsy of de novo skin eruptions or worsening of pre-existing dermatosis is strongly recommended in patients receiving any immunosuppressive therapy. AHSCT, Allogeneic hematopoietic stem cell transplant; ALZ, alemtuzumab; AWD, alive with disease; AWOD, alive without disease; AZA, azathioprine; B, black; BXT, bexarotene; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone; CsA, cyclosporine A; CTCL, cutaneous T-cell lymphoma; DOD, dead of disease; DXA, dexamethasone; ECP, photopheresis; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; F, female; f/u, follow-up; FM, fludarabine/melphalan; FMF, folliculotropic mycosis fungoides; GM, gemcitabine; H, Hispanic; HDAC, histone deacetylase inhibitor (romidepsin); INF, interferon; LCT, large cell transformation; LyP, lymphomatoid papulosis; M, male; MF, mycosis fungoides; MMF, mycophenolate mofetil; MOGA, mogalimumab; 6-MP, 6-mercaptopurine; MTX, methotrexate; N/A, not available/not applicable; NB-UVB, narrowband ultraviolet; NM, nitrogen mustargen; NOS, not otherwise specified; P, prednisone; PCAEC-TCL, primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma; PCgdTCL, primary cutaneous gd T-cell lymphoma; PUVA, psoralenultraviolet; PXT, pralatrexate; SS, S ezary syndrome; TSEBT, total skin electron beam therapy; UK, unknown; W, white; XRT, radiation therapy. AL, Atypical lymphocytes; CTCL, cutaneous T-cell lymphoma; FMF, folliculotropic mycosis fungoides; L, lymphoma; LCT, large cell transformation; LyP, lymphomatoid papulosis; MF, mycosis fungoides; N/A, not available; NOS, not otherwise specified; PCAEC-TCL, primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma; PCgdTCL, primary cutaneous gd T-cell lymphoma; SS, S ezary syndrome.
